The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Enter: Journavx, the first pain medication of its kind approved by the U.S. Food & Drug Administration in 25 years. Journavx (suzetrigine) is a new nonopioid medication manufactured by Vertex ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.

Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

New Orleans-based investment network Gulf South Angels is investing in non-opioid pain drug startup South Rampart Pharma as ...

Sold as Journavx, the drug received U.S. approval in late January as a treatment for the short-lived “acute” pain typically felt after an operation or accident. Journavx works differently than ...

The medication, called Journavx, got US regulatory clearance in January. The financial success of new drugs largely depends on how they’re treated by pharmacy benefit managers that determine ...

One point of concern shared by local recovery advocates is the possible loss of state and federal grants that pay for Narcan distribution programs. "If we don't have Narcan available, then people are ...